Risk of Gastrointestinal Perforation in Patients With Rheumatic Diseases Exposed to Janus Kinase Inhibitors Versus Adalimumab: A Nationwide Cohort Study.
Lea HoisnardAntoine MeyerRosemary Dray-SpiraAlain WeillMahmoud ZureikEmilie SbidianPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2024)
In this nationwide cohort study, the rates of GIPs did not differ between groups of patients who received JAKi and adalimumab treatment. These results need to be confirmed in other observational studies.